Collectively, our pan-cancer analysis revealed that elevated PIEZO1 expression correlates with features of advanced and aggressive disease across multiple malignancies, including higher tumor grade (BLCA, PAAD), advanced stage (LIHC), metastatic potential (SARC), and hormone receptor negativity (BRCA). This evidence concerns the gene PIEZO1 and neoplasm.